Answers are grounded in this paper and cite their sources.
This paper discusses the advantage of using repeated outcome measurements on subjects in a clinical trial. We choose the number of subjects and the number of repeated outcome measurements to minimize a given cost function so that the clinical trial has power (1-beta) for specified significance level alpha. An example illustrates the results and emphasizes the importance of study design and of critical evaluation of how one measures the study endpoint.
No takes yet. Share an insight, caveat, or question.
D. Blöch (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: